Download PDF
Thromb Haemost 2020; 120(07): 1056-1065
DOI: 10.1055/s-0040-1710591
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients

Iris van Moort 
1   Department of Pediatric Hematology, Erasmus University Medical Center – Sophia Children's Hospital, Rotterdam, The Netherlands
,
Laura H. Bukkems 
2   Department of Clinical Pharmacology – Hospital Pharmacy, Amsterdam University Medical Center, Amsterdam, The Netherlands
,
Jessica M. Heijdra
1   Department of Pediatric Hematology, Erasmus University Medical Center – Sophia Children's Hospital, Rotterdam, The Netherlands
,
Roger E. G. Schutgens
3   Van Creveldkliniek, University Medical Center Utrecht, Utrecht, The Netherlands
,
Britta A. P. Laros-van Gorkom
4   Department of Thrombosis and Hemostasis, Radboud University Medical Center, Nijmegen, The Netherlands
,
Laurens Nieuwenhuizen
5   Department of Internal Medicine, Maxima Medical Center, Veldhoven, The Netherlands
,
Felix J. M. van der Meer
6   Division of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
,
Karin Fijnvandraat
7   Department of Pediatric Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands
8   Department of Molecular and Cellular Hemostasis, Sanquin Research, Amsterdam, The Netherlands
,
Paula Ypma
9   Department of Hematology, Haga Hospital, The Hague, The Netherlands
,
Moniek P. M. de Maat 
10   Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
,
Frank W. G. Leebeek
10   Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
,
Karina Meijer
11   Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands
,
Jeroen Eikenboom
6   Division of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
,
Ron A. A. Mathôt
2   Department of Clinical Pharmacology – Hospital Pharmacy, Amsterdam University Medical Center, Amsterdam, The Netherlands
,
Marjon H. Cnossen
1   Department of Pediatric Hematology, Erasmus University Medical Center – Sophia Children's Hospital, Rotterdam, The Netherlands
,
for the OPTI-CLOT Study Group › Author Affiliations Funding This study is part of the research program of the international multicenter OPTI-CLOT consortium (Patient tailOred PharmacokineTIc-guided dosing of CLOTting factor concentrate and DDAVP in bleeding disorders), which aims to implement PK-guided dosing of clotting factor replacement therapy by initiating studies that emphasize the impact of PK-guided dosing, by constructing prophylactic and on-demand dosing population PK models, and by evaluating cost-effectiveness of a PK-guided approach. This specific project was funded by an investigator-initiated research grant from the Dutch Research Institute NWO-ZonMW with co-financing by Baxter. A complete list of OPTI-CLOT research program members is available in the [Supplementary Material] (available in the online version).
Further Information

Publication History

13 March 2020

13 April 2020

Publication Date:
01 June 2020 (online)

Also available at
    Permissions and Reprints

Abstract

Background von Willebrand factor (VWF) is crucial for optimal dosing of factor VIII (FVIII) concentrate in hemophilia A patients as it protects FVIII from premature clearance. To date, it is unknown how VWF behaves and what its impact is on FVIII clearance in the perioperative setting.

Aim To investigate VWF kinetics (VWF antigen [VWF:Ag]), VWF glycoprotein Ib binding (VWF:GPIbM), and VWF propeptide (VWFpp) in severe and moderate perioperative hemophilia A patients included in the randomized controlled perioperative OPTI-CLOT trial.

Methods Linear mixed effects modeling was applied to analyze VWF kinetics. One-way and two-way analyses of variance were used to investigate perioperative VWFpp/VWF:Ag ratios and associations with surgical bleeding.

Results Fifty-nine patients with median age of 48.8 years (interquartile range: 34.8–60.0) were included. VWF:Ag and VWF:GPIbM increased significantly postoperatively. Blood type non-O or medium risk surgery were associated with higher VWF:Ag and VWF:GPIbM levels compared with blood type O and low risk surgery. VWFpp/VWF:Ag was significantly higher immediately after surgery than 32 to 57 hours after surgery (p < 0.001). Lowest VWF:Ag quartile (0.43–0.92 IU/mL) was associated with an increase of FVIII concentrate clearance of 26 mL/h (95% confidence interval: 2–50 mL/h) compared with highest VWF antigen quartile (1.70–3.84 IU/mL). VWF levels were not associated with perioperative bleeding F(4,227) = 0.54, p = 0.710.

Conclusion VWF:Ag and VWF:GPIbM levels increase postoperatively, most significantly in patients with blood type non-O or medium risk surgery. Lower VWF antigen levels did not lead to clinically relevant higher FVIII clearance. VWF:Ag or VWF:GPIbM levels were not associated with perioperative hemorrhage.

Keywords

hemophilia A - von Willebrand factor - surgery - factor VIII - linear mixed effect modeling - postsurgical bleeding

Authors' Contributions

M.C., I.M., and H.C.A.M.H. were responsible for protocol design and study implementation. I.M. enrolled patients, performed blood sampling for PK analysis, collected data, performed statistical analyses, and is main author of the manuscript together with M.C. L.B. performed population pharmacokinetic calculations. R.S., B.L., L.H., F.M., K.F., F.L., and K.M. monitored patient inclusion. M.C., R.M., J.E., F.L., K.F., K.M., and M.d.M. gave critical guidance during the project. M.C. and R.M. supervised the study. All authors substantially contributed to the writing and critically revised the manuscript, with approval of the final draft.


Supplementary Material

 

  • References

  • 1 Srivastava A, Brewer AK, Mauser-Bunschoten EP. , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
    CrossrefPubMedSearch in Google Scholar
  • 2 Hazendonk HC, Lock J, Mathôt RA. , et al. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications. J Thromb Haemost 2016; 14 (03) 468-478
    CrossrefPubMedSearch in Google Scholar
  • 3 Leebeek FWG, Mauser-Bunschoten EP. Richtlijn diagnostiek en behandeling van hemofilie en aanverwante hemostase stoornissen. Utrecht: Van Zuiden Communications BV; 2009
    Search in Google Scholar
  • 4 Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood 2016; 128 (16) 2007-2016
    PubMedSearch in Google Scholar
  • 5 Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91 (02) 474-476
    CrossrefPubMedSearch in Google Scholar
  • 6 Kahlon A, Grabell J, Tuttle A. , et al. Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals. Haemophilia 2013; 19 (05) 758-764
    CrossrefPubMedSearch in Google Scholar
  • 7 Hazendonk HC, van Moort I, Fijnvandraat K. , et al. The “OPTI-CLOT” trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A. Thromb Haemost 2015; 114 (03) 639-644
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Koshy M, Weiner SJ, Miller ST. , et al; Cooperative Study of Sickle Cell Diseases. Surgery and anesthesia in sickle cell disease. Blood 1995; 86 (10) 3676-3684
    CrossrefPubMedSearch in Google Scholar
  • 9 Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8 (01) 202-204
    CrossrefPubMedSearch in Google Scholar
  • 10 Sanders YV, Groeneveld D, Meijer K. , et al; WiN study group. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood 2015; 125 (19) 3006-3013
    CrossrefPubMedSearch in Google Scholar
  • 11 Hazendonk H, Fijnvandraat K, Lock J. , et al; “OPTI-CLOT” study group. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica 2016; 101 (10) 1159-1169
    CrossrefPubMedSearch in Google Scholar
  • 12 Jonsson EN, Karlsson MO. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58 (01) 51-64
    PubMedSearch in Google Scholar
  • 13 van Loon JE, Sonneveld MA, Praet SF, de Maat MP, Leebeek FW. Performance related factors are the main determinants of the von Willebrand factor response to exhaustive physical exercise. PLoS One 2014; 9 (03) e91687
    CrossrefPubMedSearch in Google Scholar
  • 14 Claus RA, Bockmeyer CL, Sossdorf M, Lösche W, Hilberg T. Physical stress as a model to study variations in ADAMTS-13 activity, von Willebrand factor level and platelet activation. J Thromb Haemost 2006; 4 (04) 902-905
    CrossrefPubMedSearch in Google Scholar
  • 15 Borchiellini A, Fijnvandraat K, ten Cate JW. , et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996; 88 (08) 2951-2958
    CrossrefPubMedSearch in Google Scholar
  • 16 Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986; 46 (02) 185-190
    CrossrefPubMedSearch in Google Scholar
  • 17 Castaman G, Tosetto A, Eikenboom JC, Rodeghiero F. Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza. J Thromb Haemost 2010; 8 (09) 2078-2080
    CrossrefPubMedSearch in Google Scholar
  • 18 Sanders YV, Giezenaar MA, Laros-van Gorkom BA. , et al; WiN study group. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost 2014; 12 (07) 1066-1075
    CrossrefPubMedSearch in Google Scholar
  • 19 Atiq F, Fijnvandraat K, van Galen KPM. , et al; WiN study group. BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease. Am J Hematol 2019; 94 (08) E201-E205
    PubMedSearch in Google Scholar
  • 20 Loomans JI, Stokhuijzen E, Peters M, Fijnvandraat K. Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner. J Clin Transl Res 2018; 3 (Suppl. 02) 351-357
    PubMedSearch in Google Scholar